Incidence and bone biopsy findings of atypical femoral fractures

Journal of Bone and Mineral Metabolism

Volumn 31, Issue 5, 2013, Pages 585-594

  Tamminen, Inari S ^a,b   Yli Kyyny, Tero ^b   Isaksson, Hanna ^a,c   Turunen, Mikael J ^a,b   Tong, Xiaoyu ^a,b   Jurvelin, Jukka S ^a   Kröger, Heikki ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Bisphosphonates; Bone histomorphometry; FTIRI; Iliac crest; Trabecular bone

Indexed keywords

ALENDRONIC ACID; AMIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; BIMATOPROST; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN; DILTIAZEM; FLUTICASONE PROPIONATE PLUS SALMETEROL; IBANDRONIC ACID; PHOSPHATE; TETRACYCLINE; VITAMIN D;

ADULT; AGED; ARTICLE; ATYPICAL FEMORAL FRACTURE; BONE BIOPSY; BONE MINERALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FEMUR FRACTURE; FINLAND; HUMAN; HUMAN TISSUE; INCIDENCE; INFRARED SPECTROSCOPY; INTRAMEDULLARY NAIL; MALE; MEDICAL RECORD; MORPHOMETRICS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; QUANTITATIVE ANALYSIS; TRABECULAR BONE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOPSY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; MIDDLE AGED;

EID: 84885420745     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-013-0448-7     Document Type: Article

References (35)

1. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RWJ, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
3. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
4. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
6. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
7. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306
8. Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948-2952
9. Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095-1102
10. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
11. Schilcher J, Aspenberg P (2009) Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 80:413-415
12. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC (2010) Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771
13. Whyte MP, Bergfeld MA, Murphy WA, Avioli LV, Teitelbaum SL (1982) Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of iliac crest bone from untreated patients. Am J Med 72:193-202
14. Hauge E, Mosekilde L, Melsen F (1999) Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 25:389-395
15. Boskey A, Mendelsohn R (2005) Infrared analysis of bone in health and disease. J Biomed Opt 10:031102
16. Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL (2012) Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 27:672-678
17. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610
18. Recker RR, Kimmel DB, Parfitt AM, Davies KM, Keshawarz N, Hinders S (1988) Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J Bone Miner Res 3:133-144
19. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB (2011) Issues in modern bone histomorphometry. Bone 49:955-964
20. Tamminen IS, Mayranpaa MK, Turunen MJ, Isaksson H, Makitie O, Jurvelin JS, Kroger H (2011) Altered bone composition in children with vertebral fracture. J Bone Miner Res 26:2226-2234
21. Isaksson H, Turunen MJ, Rieppo L, Saarakkala S, Tamminen IS, Rieppo J, Kroger H, Jurvelin JS (2010) Infrared spectroscopy indicates altered bone turnover and remodeling activity in renal osteodystrophy. J Bone Miner Res 25:1360-1366
22. Boskey A (2003) Bone mineral crystal size. Osteoporos Int 14 Suppl 5:S16-S20 (discussion S20-1)
23. Boskey A, Pleshko Camacho N (2007) FT-IR imaging of native and tissue-engineered bone and cartilage. Biomaterials 28:2465-2478
24. Huang RY, Miller LM, Carlson CS, Chance MR (2002) Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. Bone 30:492-497
25. Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M (2001) Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 16:1821-1828
26. Boskey AL, Spevak L, Weinstein RS (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20:793-800
27. Turunen MJ, Saarakkala S, Helminen HJ, Jurvelin JS, Isaksson H (2012) Age-related changes in organization and content of the collagen matrix in rabbit cortical bone. J Orthop Res 30:435-442
28. Takada J, Katahira G, Iba K, Yoshizaki T, Yamashita T (2011) Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis. J Bone Miner Metab 29:458-465
29. Eriksen EF, Melsen F, Sod E, Barton I, Chines A (2002) Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31:620-625
30. Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, Garcia-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF (2008) Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 23:6-16
31. Boskey AL, DiCarlo E, Paschalis E, West P, Mendelsohn R (2005) Comparison of mineral quality and quantity in iliac crest biopsies from high- and low-turnover osteoporosis: an FT-IR microspectroscopic investigation. Osteoporos Int 16:2031-2038
32. Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL (2004) Bone fragility and collagen cross-links. J Bone Miner Res 19:2000-2004
33. Bala Y, Depalle B, Farlay D, Douillard T, Meille S, Follet H, Chapurlat R, Chevalier J, Boivin G (2012) Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res 27:825-834
34. Gourion-Arsiquaud S, Faibish D, Myers E, Spevak L, Compston J, Hodsman A, Shane E, Recker RR, Boskey ER, Boskey AL (2009) Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture. J Bone Miner Res 24:1565-1571
35. Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL (2010) Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46:666-672